Gathering Wisdom and Strength | Professor Liu Yuanzhao’s Deep Empowerment Marks a New Journey for Our Hospital's Cancer Treatment

Recently, Professor Liu Yuanzhao, Director of the Stereotactic Radiotherapy Committee of the National Industrial Alliance for Tumor Minimally Invasive Therapy and Chief Physician of the Radiotherapy Department at Beijing Hospital, has officially joined the Lanzhou Heavy Ion Center of Gansu Wuwei Cancer Hospital in a regular resident mode. This infusion of expertise provides new, powerful momentum for the development of our hospital in the field of cancer treatment.

As a Chief Physician and Master's Supervisor, Professor Liu Yuanzhao's professional background is highly distinguished. He holds several important positions, including Standing Committee Member of the Nasopharyngeal Cancer Prevention and Treatment Branch of the China International Exchange and Promotive Association for Medical and Health Care, and Vice Chairman of the Head and Neck Tumor Molecular Diagnosis and Treatment Committee of the Beijing Anti-Cancer Association. He also serves as an editorial board member for the Chinese Journal of Metastatic Tumorsand the Chinese Journal of Minimally Invasive Surgery, and acts as an expert for Beijing municipal bidding and medical record quality appraisal, continuously guiding the direction of radiotherapy technology at the national level.

In clinical practice, Professor Liu's strengths align precisely with the center's needs. With many years of experience in tumor radiotherapy, he is particularly skilled in the diagnosis and treatment of head and neck tumors, having treated nearly a thousand patients with head and neck tumors using X-ray stereotactic therapy. In recent years, he has focused more on high-dose irradiation for early-stage tumors and image-guided intensity-modulated radiotherapy, successfully achieving curative effects for elderly cancer patients.

Since joining, Professor Liu has quickly integrated into the team and deeply involved himself in core activities. He insists on conducting regular ward rounds and outpatient clinics, provides specialized guidance for complex cases, and works with the medical team to analyze conditions and optimize treatment plans.While ensuring treatment precision, he highly prioritizes patient tolerance to therapy and, through hands-on teaching, continuously enhances the overall diagnostic and treatment level of the team, enabling every cancer patient to benefit from high-quality medical services that meet international standards.

The Lanzhou Heavy Ion Center has long maintained an open approach to attracting top medical talent. It has previously appointed international authorities such as Professor Tatsuaki Kanai from Gunma University, Japan; Professor Hirohiko Tsujii, former President of the National Institute of Radiological Sciences (NIRS); Professor Jörg Hauffe, former Director of the Rinecker Proton Therapy Center (RPTC), Munich, Germany; Professor Olga; Professor Yi-Min Ren, former Chairman of the Taiwan Society of Therapeutic Radiation Oncology; and Professor Wu Jiaming, a renowned radiotherapy physicist from Taiwan's Chang Gung Memorial Hospital. These collaborations have promoted the alignment of Chinese standards with international practices through technical exchanges. Recently, the center further introduced Professor Yasuo Yoshioka from the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, and Professor György Kovács, Director of the Brachytherapy Center at the University of Lübeck, Germany (who also serves as Director of Educational Programs at the Università Cattolica del Sacro Cuore, Italy), for long-term resident work. They integrate Chinese diagnostic and treatment standards into clinical teaching and technical guidance, laying a solid foundation for building a tumor treatment system with international competitiveness and a platform for standard dissemination.

This philosophy of "gathering outstanding talents from around the world and putting them to good use" has created a foundation for Professor Liu's rapid integration into the team, allowing him to quickly combine his technical strengths with the center's existing resources to form a stronger diagnostic and therapeutic synergy.

Guided by leading figures like Professor Liu Yuanzhao, the Lanzhou Heavy Ion Center is accelerating its advancement towards becoming an internationally top-tier heavy ion tumor diagnosis and treatment center, integrating clinical services, scientific research translation, and talent cultivation.

In the future, the center will steadily promote the establishment of a heavy ion treatment alliance and the setup of 50 expert workstations, continuously consolidating strengths to break through challenges in cancer treatment and bring new hope to cancer patients globally.

Lanzhou Heavy Ion Center

Gansu Wuwei Cancer Hospital is a state-owned public Third Grade Class A specialized cancer hospital.

The Lanzhou Heavy Ion Center is the second clinical application center for heavy ion therapy in China operated by Gansu Wuwei Cancer Hospital, utilizing China's proprietary intellectual property. The second Chinese heavy ion tumor treatment system commenced clinical operations at the Lanzhou Heavy Ion Center on November 15, 2024. To date, the center has treated over 300 patients with photon and heavy ion therapy, covering disease types such as lung cancer, pancreatic cancer, liver cancer, and brain glioma.

The Lanzhou Heavy Ion Center has established an elite talent system, building expert workstations led by 50 top authorities in the field, including Professor Shen Wenjiang, Lifetime Honorary Professor of the Department of Radiation Oncology at Peking University Health Science Center, and Professor Xu Bo, Standing Committee Member of the Chinese Medical Association's Radiotherapy Oncology Branch. With Professor Wang Junjie, Chairman of the Chinese Medical Association's Society of Radiotherapy Oncology, serving as Dean, the center possesses strong technical support for heavy ion therapy.

Furthermore, the hospital campus is equipped with a series of cutting-edge medical devices, including a Varian VitalBeam medical linear accelerator, an Elekta Infinity four-dimensional image-guided linear accelerator, a 3.0T simulation and positioning MRI, a GE 256-slice high-end CT scanner, and a Varian iridium-192 imported afterloader. These hardware facilities form a solid foundation for heavy ion therapy, ensuring efficiency and precision throughout the treatment process.

Aiming to build a comprehensive, full-lifecycle cancer treatment system, the hospital has established departments including Radiotherapy, Oncology/Hematology, Surgical Oncology, Integrated Chinese and Western Medicine for Oncology Rehabilitation, Intensive Care Medicine, Digestive Endoscopy Center, Imaging Department, Clinical Laboratory, Ultrasound Department, Blood Bank, and Hematology Center Laboratory. It provides comprehensive treatments such as photon radiotherapy, chemotherapy, heavy ion therapy, internal medicine, and surgical oncology, alongside services including medical imaging, laboratory testing, ultrasonography, and bone marrow cell morphology examinations.

Lanzhou Heavy Ion Center Consultation Hotline：

Director Li: +86 1660935 3666

Teacher Yan: +86 176 9325 0603

Preliminary Review: Zhang Lihong  

Final Review: Zhang Jie